Exact Sciences Corp. (NASDAQ:EXAS) announced Wednesday that its Oncodetect molecular residual disease test has secured Medicare coverage through the Centers for Medicare & Medicaid Services for patients with stage II, III, and resectable stage IV colorectal cancer.
The coverage, approved through the Molecular Diagnostic Services Program, allows for serial use of the test in adjuvant and recurrence monitoring settings over a five-year period, according to a company press release.
The Oncodetect test is designed to track up to 200 circulating tumor DNA variants and can potentially identify cancer recurrence up to two years earlier than imaging alone. The test provides quantitative assessment of circulating tumor DNA to help healthcare providers understand a patient’s molecular residual disease status.
"Gaining Medicare coverage for the Oncodetect test is a meaningful step forward in expanding access to earlier, more personalized insights for patients with colorectal cancer," said Brian Baranick, Executive Vice President and General Manager of Precision Oncology at Exact Sciences.
The company stated that more than three million Americans are eligible for molecular residual disease testing across multiple solid tumors. Exact Sciences is pursuing additional Medicare coverage for other solid tumor indications.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.